Clinical Trial Results: Positive or negative results from clinical trials of Annovis Bio's drug candidates, particularly Posiphen, significantly impact stock price. Positive data often leads to price increases, while negative data can cause declines.

Regulatory Milestones: Key regulatory events, such as FDA approval pathways (e.g., Breakthrough Therapy designation) or approval decisions, are critical drivers. Positive regulatory developments typically boost the stock.

Financial Performance: Annovis Bio's cash runway, burn rate, and ability to secure funding influence investor sentiment. Concerns about liquidity can negatively affect the stock.

Competition: Developments in competing Alzheimer's and Parkinson's disease treatments can impact ANVS.US. The success of rival drugs could reduce the perceived value of Annovis Bio's pipeline.

Market Sentiment: General market trends, particularly within the biotechnology sector, can influence the stock. Positive market sentiment tends to lift biotech stocks, while negative sentiment can depress them.

News & Announcements: Major announcements from Annovis Bio, such as partnerships, collaborations, or presentations at scientific conferences, can affect the stock price.

Analyst Ratings: Analyst ratings and price targets can sway investor opinion. Upgrades often lead to price increases, while downgrades can cause declines.

Intellectual Property: The strength and scope of Annovis Bio's patents protecting its drug candidates are important. Strong IP positions provide greater security and potential for future revenue.

Management Team: Investor confidence in the management team and their ability to execute on the company's strategy is a factor. Changes in management can also affect the stock.

Macroeconomic Factors: Broader economic conditions, such as interest rates and inflation, can influence investor appetite for riskier assets like biotechnology stocks.